Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 3—March 2011

Research

Monitoring and Characterization of Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, Japan, 2009–2010

Makoto Ujike, Miho Ejima, Akane Anraku, Kozue Shimabukuro, Masatsugu Obuchi, Noriko Kishida, Xu Hong, Emi Takashita, Seiichiro Fujisaki, Kazuyo Yamashita, Hiroshi Horikawa, Yumiko Kato, Akio Oguchi, Nobuyuki Fujita, Masato Tashiro, Takato OdagiriComments to Author , and the Influenza Virus Surveillance Group of Japan
Author affiliations: Author affiliations: National Institute of Infectious Diseases, Tokyo, Japan (M. Ujike, M. Ejima, A. Anraku, K. Shimabukuro, M. Obuchi, N. Kishida, X. Hong, E. Takashita, S. Fujisaki, K. Yamashita, M. Tashiro, T. Odagiri); National Institute of Technology and Evaluation, Tokyo (H. Horikawa, Y. Kato, A. Oguchi, N. Fujita)

Main Article

Table1

Relationship between detection of oseltamivir-resistant pandemic (H1N1) 2009 and interval from oseltamivir treatment to sample collection, Japan, 2009–2010*

No. samples
Days after oseltamivir treatment, N = 516†
Unknown
0‡
1
2
3
4
5
6
7
8
9
>10
Total no. 169 54 116 54 37 31 36 7 6 1 3 2
No. oseltamivir-resistant pandemic (H1N1) 2009 3 0 4 2 4 (1) 13 (1) 19 (1) 3 (2) 2 1 (1) 2 (2) 2 (2)

*Of total 4,307 specimens tested, neuraminidase inhibitor treatment history was available for 1,707; of these specimens, 516 were from patients who had received oseltamivir treatment.
†Parentheses indicate prophylactic use, e.g., 4 (1) = 1 of 4 total uses was for prophylaxis.
‡Day 0 represents the samples collected within 24 h after oseltamivir use.

Main Article

1Members of the Influenza Virus Surveillance Group of Japan are listed at the end of this article.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO